REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia) was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (known as the REMAP-COVID sub-study in the U.S.), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. The main objective of REMAP-CAP: COVID is to reduce mortality and morbidity in patients hospitalized with COVID-19 infection.

Global Coalition for Adaptive Research (GCAR) serves at the US Sponsor for the REMAP-COVID trial alongside University of Pittsburgh, the US Regional Coordinating Center. The Immunomodulation Domain (REMAP-COVID IM-2 DSA) began with the evaluation of multiple drugs.

Currently in the U.S., 2 domains for the REMAP-CAP: COVID trial are active: the Immune Modulation 2 Domain (REMAP-COVID IM-2 DSA) and the Vitamin C Domain (REMAP-COVID Vit-C DSA). Patients were initially enrolled in these domains at the first active site, University of Pittsburgh, in October 2020. More than 15 sites in the US are now recruiting.


Video credit: University of Pittsburgh


For more information regarding the trial please visit:




Questions, please email